A pragmatic, multicentre, placebo controlled, double blind, parallel, randomised controlled trial of liquid alginate (Gaviscon Advance) for the treatment of persistent throat symptoms

 Study Stage: Set-up

• Sponsor:  The Newcastle upon Tyne Hospitals NHS Foundation Trust
• Funder:  IIT (Reckitt)
• Therapeutic area: Ear, Nose and Throat
• Type of study: CTIMP

Aim: To compare the symptomatic response in patients with persistent throat symptoms to a liquid alginate (Gaviscon Advance) compared to matched placebo.

Primary Outcome: Total Reflux Symptom Index (RSI) score at 8 weeks

• Clinical Phase: III
• Population: Adult
• Design: Randomised, double-blind, placebo-controlled, parallel designed trial
• Setting: Secondary Care
• Planned Sample Size: 250